title: Nuvance (Immunex).
abstract: Immunex is carrying out worldwide phase II trials on a genetically-engineered soluble interleukin-4 receptor (IL-4R, Nuvance), administered as a nebulized liquid, for the potential treatment of allergic asthma. IL-4R may also be of use in the treatment of organ transplant rejection, graft versus host disease, allergy and infectious disease.
authors.affiliation: Department of Environmental Occupational Health, University of Pittsburgh, RIDC Park, Pittsburgh, PA 15238, USA. lange@pop.pitt.edu
authors.forename: R W
authors.initials: RW
authors.lastname: Lange